A Switch for Stronger Bones? Researchers Discover a New Approach to Treating Osteoporosis

A receptor that has received little attention to date could play an important role in maintaining bone strength. Researchers at the University of Leipzig have shown that the GPR133 receptor can be specifically activated—and that this increases bone formation and slows bone loss in mice. What’s particularly interesting is that the same molecular approach has previously been linked to improved muscle strength. However, there is still a long way to go before it can be applied in humans.

A Receptor that Can Respond to Stress

Osteoporosis often develops unnoticed over a long period of time. While bone density gradually decreases, those affected often experience no symptoms at first. The disease only becomes apparent when a bone fractures during a relatively minor fall or other stress. This is why a strong skeletal system becomes increasingly important as people age. According to the University of Leipzig, approximately six million people in Germany alone live with osteoporosis, with women being particularly affected. The search for new treatment options is therefore increasingly focusing on biological mechanisms that could directly influence bone formation. This is precisely where the research from Leipzig comes in.

The focus is on GPR133, a receptor belonging to the group of so-called adhesion G-protein-coupled receptors. These proteins are located on the surface of cells and can receive signals from their environment and transmit them within the cell. GPR133 is by no means a classic “bone receptor” of the kind that has been the focus of osteoporosis research for years. Rather, it belongs to a group of receptors whose functions are only gradually being unraveled. The research from Leipzig now provides evidence that GPR133 is closely linked to the regulation of bone tissue.

Of particular interest is the connection between the receptor and mechanical stimuli. Bone is not a static material. It is constantly being remodeled and adapts, among other things, to the stresses to which it is exposed. GPR133 appears to be involved in this interaction between mechanical forces and the signals from bone cells.

Bones Are Constantly Undergoing Remodeling

To understand the significance of the receptor, it is worth taking a look at normal bone metabolism. Our skeleton is renewed throughout our lives. Various cell types work together in this process. Osteoblasts build new bone tissue, while osteoclasts break down existing bone tissue. This breakdown is not, in principle, a pathological process; it is part of the skeleton’s normal renewal process.

The key factor is the balance between these two processes. If bone resorption predominates over the long term, the skeleton loses substance and stability. This is exactly what can happen in osteoporosis. The Leipzig studies suggest that GPR133 plays a role in this balance: When the receptor is activated, bone-forming processes are promoted, while the activity of bone-resorbing cells decreases. GPR133 could thus act at a point that is crucial for skeletal stability: not only in protecting existing bone mass but also in promoting its formation.

AP503 Activates the Molecular Mechanism

To this end, the researchers investigated, among other substances, AP503. It was identified as an activator of GPR133 using computer-aided screening. In the experiments, the receptor was specifically stimulated. In mice, the treatment led to changes in bone structure and increased resilience of the bone tissue. Positive effects were also observed in animals whose bones were weakened by an osteoporosis model.

The original study describes, among other things, an increase in bone volume as well as changes to the so-called trabeculae. These are the fine, sponge-like structures found inside many bones. In addition, more osteoblasts and osteocytes, as well as fewer osteoclasts, were observed. In mechanical tests, the bones of the treated animals proved to be more resilient.

This is an important distinction from a mere change in a laboratory value: The researchers examined not only molecular signaling pathways but also structural properties and the mechanical resilience of the bone.

Why Mechanical Loading is Particularly Interesting

Bones respond to their environment. When subjected to regular mechanical loading, cells within the bone can detect these mechanical stimuli and trigger corresponding biological processes. GPR133 appears to be involved in this mechanism. The research suggests that the receptor processes signals arising from the interaction between mechanical stress and cell-cell contacts. Through downstream signaling pathways, this can influence processes that are important for the differentiation and activity of osteoblasts.

Thus, the receptor could represent a kind of link between mechanical stress on the skeleton and its biological adaptation. This is of interest to osteoporosis research because, in a weakened skeleton, it is not only the amount of available bone material that is decisive. Its architecture and ability to withstand mechanical stress also play a key role in determining fracture risk.

Particularly Exciting: Bones and Muscles Simultaneously

The Leipzig research could be interesting for another reason as well. AP503 had previously been studied in connection with skeletal muscle. In an earlier study, the scientists found evidence that activation of GPR133 can improve muscle strength and the contractility of skeletal muscle. The bone studies now provide evidence that the same receptor also affects the skeleton.

This interaction is particularly relevant in older age, as muscle and bone loss often occur together. Reduced muscle strength can impair mobility and stability, while decreased bone strength increases the risk of injury.

An active ingredient that could influence both tissues would therefore be of particular scientific interest. However, this is still a research concept and not an established treatment.

What Happens With Osteoporosis After Menopause

A potential target group for future therapies would be people with age- or hormone-related bone loss. In women in particular, bone metabolism changes after menopause. As estrogen levels drop, the balance between bone formation and bone resorption can shift. Bone tissue is then broken down faster than new tissue can be formed. The internal structure of the bone can also change: the fine, spongy structures become thinner and more unstable, reducing the skeleton’s load-bearing capacity.

Normally, bone undergoes a constant process of renewal. Osteoclasts break down old bone tissue, while osteoblasts form new tissue. The Leipzig research approach focuses precisely on this balance. The scientists investigated whether the activity of these cells could be influenced via the GPR133 receptor. In the experiments, activation of the receptor with AP503 was associated with increased bone formation and reduced osteoclast activity.

For the studies, the researchers used, among other things, mice in which osteoporosis-like bone loss had been induced. In the treated animals, activation of GPR133 led to changes in bone structure and increased mechanical strength. Interestingly, the approach is not intended solely to slow bone resorption. Rather, the goal is to shift the balance between resorption and formation in favor of more stable bones.

However, it cannot yet be concluded that AP503 would also help women with postmenopausal osteoporosis. The results to date come from preclinical studies, and a mouse model only provides a simplified representation of the human disease. Further studies must therefore clarify whether the mechanism also works in humans, what dosage would be necessary, and whether long-term activation of GPR133 is safe.

Furthermore, the exact function of the receptor in the human body is not yet fully understood. GPR133 is not found exclusively in bone, which is why potential effects on other tissues must also be investigated. Before AP503 or a similar active ingredient could be developed into a treatment, further preclinical studies and subsequent clinical trials in humans would therefore be necessary. The results thus primarily point to a new biological mechanism. GPR133 could play a previously overlooked role in regulating bone stability. Whether this can actually lead to the development of a new therapy for osteoporosis—which frequently occurs after menopause—remains to be seen through further research

It’s a Long Road from Mice to Humans

This point is particularly crucial when it comes to new active compounds. Promising results in cell cultures or animal models are an important prerequisite for further development, but they cannot replace clinical trials.

For AP503, therefore, the focus is initially on further basic and preclinical research. Among other things, the Leipzig scientists are investigating the exact function of GPR133 and the receptor’s potential applications. The question of whether activation of the receptor can be specifically limited to certain signaling pathways could also play a role in the future development of a drug. The University of Leipzig has been conducting intensive research on so-called adhesion GPCRs for years, investigating how these receptors are activated and how they transmit signals within cells.

GPR133 is part of a larger family of receptors whose medical potential is only gradually becoming apparent. According to the University of Leipzig, numerous adhesion-GPCRs have now been linked to various diseases. At the same time, there is as yet no approved drug that specifically targets such a receptor for therapeutic purposes.

This makes the Leipzig research program particularly interesting from a scientific perspective. Rather than simply refining an already known mechanism, the scientists are attempting to decipher the function of a comparatively little-studied receptor and derive potential new therapeutic approaches from it. In the long term, this could lead to a new approach for osteoporosis: not only slowing bone resorption but also specifically stimulating the body’s own bone-formation processes at the same time.

Not Yet a New Osteoporosis Treatment, But an Interesting Approach

The results thus provide important insight into the role GPR133 might play in bone biology. In mice, activating the receptor increased bone formation and improved the mechanical stability of the bone. At the same time, there are indications of a possible positive effect on the muscles. Whether this will actually lead to a drug for osteoporosis remains to be seen. Several development phases and clinical trials lie between a successful animal study and an approved treatment.

Nevertheless, the discovery expands our understanding of how bones regulate their stability. If the mechanism is confirmed in humans as well, GPR133 could become an interesting target in the future for drugs that act simultaneously on bone and possibly muscle tissue. The next phase of research in Leipzig will therefore aim to clarify the receptor’s functions throughout the body, how AP503 works exactly, and whether this approach can also be applied to other diseases.